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Oral cancer is one of the ten most common malignancies in the
world, with a prevalence varying from 1–2% of total malignancies
in Japan, the UK and the USA to 30–40% in India, Bangladesh and
Pakistan, and with 90–95% of all cases presenting histologically as
squamous cell carcinomas (SCCs) (Johnson, 1991). The patho-
genesis of tumour development in the oral cavity is still not well
understood, but oral leukoplakia and erythroplakia are widely
recognized as the major premalignant states of oral SCCs. The
lesions, which are defined clinically as white and red patches,
initially show benign hyperkeratosis, and then, in more than 10%
of the lesions showing microscopic dysplasia, transform to SCCs
within a decade (Silverman et al, 1984).
It is well accepted that multiple genetic alterations are involved
in the tumorigenic process of human cancers, and both mutation or
overexpression of oncogenes and loss of tumour suppressor genes
are often observed in various cancer tissues and cell lines.
Complex patterns of such alterations have also been reported
during the carcinogenesis of oral SCCs, and the tumour is believed
to progress through a series of accumulations of genetic alterations
in the same manner as other cancers (Papadimitrakopoulou et al,
1996; Todd et al, 1997).
Recently, the human fragile histidine triad (FHIT) gene has been
identified at 3p14.2 using an exon-trapping strategy from cosmids
covering this region, including the FRA3B fragile site in an epithe-
lial cancer cell line (Ohta et al, 1996). It has been extensively
reported that aberrantly spliced FHIT transcripts are frequently
expressed in digestive tract, lung and breast cancers (Ohta et al,
1996; Sozzi et al, 1996; Hayashi et al, 1997). The FHIT gene alter-
ations in head and neck cancers, including oral SCCs, have also
been examined using SCC-derived cell lines (Mao et al, 1996;
Virgilio et al, 1996), because, among various genetic alterations,
loss of heterozygosity (LOH) at 3 p has frequently been reported
in oral SCCs (Maestro et al, 1993; Ah-See et al, 1994). However,
the importance of FHIT abnormalities during the process of oral
cancer development in vivo, and particularly their possible associa-
tion with hyperplastic or dysplastic lesions, is still unclear. In this
study, we examined FHIT gene abnormalities in oral SCCs to deter-
mine whether the FHIT gene is actually a frequent target for alter-
ation during oral tumorigenesis in vivo. To estimate the stage of
involvement of the FHIT gene alterations, tissue samples of several
leukoplakias and an erythroplakia were also subjected to study.
MATERIALS AND METHODS
Tissue samples
Twenty-two tissue specimens, including 15 primary oral SCCs, six
leukoplakias and one erythroplakia, were obtained from 20
patients, and these patients, each of whom was subsequently moni-
tored for at least 3 years at our clinic. The tumours were staged
according to the TNM classification of malignant tumours defined
by UICC (1987), and the patients were interviewed by the authors
in regard to their smoking and drinking habits using a standardized
questionnaire. The clinicopathological characteristics of these
cases are summarized in Table 1. In two patients, a leukoplakia
specimen and an oral SCC specimen were excised simultaneously:
in patient No. 7 the leukoplakia specimen was from the upper
gingiva on the opposite side of the incipient SCC; in patient No. 15
it was from a site adjacent to the buccal SCC. All specimens were
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chemotherapy, and cut into two pieces. One half of each sample
was subjected to isolation of RNAs immediately; the other portion,
including the surrounding normal tissue, was fixed in 10%
formalin solution for routine microscopic examination. Specimens
of apparently normal oral epithelia were also obtained from nine
cancer-free individuals as controls.
Preparation of RNA and RT-PCR
Total RNAs were prepared from 10–100 mg of human oral tissue
following the method of Chomczynski and Sacchi (1987). Reverse
transcription-polymerase chain reaction (RT-PCR) was carried out
as described previously (Hayashi et al, 1997). Oligonucleotides
used in PCR amplification of FHIT transcripts were as follows: P1
(sense strand in exons 1 and 2 of the FHIT gene according to 
Ohta et al (1996)), ATCCTGGAAGCTTTGAAGCTCA; P2 (anti-
sense strand in exon 10), TCACTGGTTGAAGAATACAGGA; P3
(sense strand in exon 3), TCCGTAGTGCTATCTACATCC; P4
(anti-sense strand in exon 10), CATGCTGATTCAGTTCCTCTTG.
The prepared RNAs (1 mg each) were reverse-transcribed to
synthesize cDNA using random hexamers at 42°C and then
subjected to the first PCR amplification with primers P1 and P2 in
20 ml of a mixture containing 10 mM Tris–HCl (pH 8.3), 50 mM
potassium chloride (KCl), 1.5 mM magnesium chloride (MgCl2)
0.01% gelatin and 0.2 mM dNTPs (dATP, dTTP, dGTP and dCTP).
PCR was performed using a GeneAmp™ PCR System 9600
(Perkin-Elmer Cetus, Norwalk, CT, USA) and consisted 
of 25 cycles of denaturing at 95°C for 30 s, annealing at 65°C for
30 s and extension at 72°C for 1 min. The amplified mixtures were
diluted 20-fold in 10 mM Tris–HCl (pH 7.5) buffer containing 
1m M EDTA, and 1 ml of the diluted mixtures was subjected to the
second round of PCR using the nested primers P3 and P4 for 30
cycles under the above conditions. The PCR products were then
subjected to 2% agarose gel electrophoresis and visualized by
ethidium bromide staining. The fractionated DNAs were trans-
ferred to a nylon membrane (Hybond-N; Amarsham, Arlington
Heights, IL, USA) and cross-linked under ultraviolet light. The
oligonucleotide encoding exon 10 was labelled with [a-32P]dATP
using the random primer method, and then used as a probe for
hybridization in 5 ´ SSC (saline-sodium citrate), 10 ´ Denhardt’s
solution, 10 mM EDTA, 200 mg/ml of salmon sperm DNA and 1%
sodium dodecyl sulphate (SDS) at 65°C. Radioactivity was then
evaluated by autoradiography with the Fuji Bio-Image Analyser
BAS 2000 (Fuji Film Co. Ltd, Tokyo, Japan).
cDNA sequencing
PCR products were cut from gels. DNAs were purified using a
Geneclean III Kit (BIO 101, Inc., Vista, CA, USA) and then
subcloned in plasmid vector pGEM7Zf(+) (Promega, Madison,
WI, USA). Sequencing was carried out using an AutoRead
Sequencing Kit (Pharmacia Biotech, Uppsala, Sweden) and an
A.L.F. DNA Sequencer II (Pharmacia LKB Biotechnology AB,
Uppsala, Sweden) with fluoro-labelled SP6 and T7 primers.
Microdissection and preparation of DNA
Genomic DNAs of six oral SCCs that had expressed abnormal
FHIT transcripts were prepared from the formalin-fixed, paraffin-
embedded tissue specimens using a microdissection technique
(Gupta et al, 1997). Briefly, the regions of SCC and normal epithe-
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Table 1 Clinicopathological characteristics of oral SCC, leukoplakia and erythroplakia patients
No. Age Sex Subsite Clinical Pathological TNM Smoking/Drinking
diagnosis diagnosis
1 71 F Lower gingiva Oral cancer SCC T2N0M0 –/–
2 64 F Tongue Oral cancer SCC T4N2cM0 –/–
3 85 F Floor of mouth Oral cancer SCC T4N2cM0 –/–
4 74 M Floor of mouth Oral cancer SCC T4N3M1 +/+
5 64 F Tongue Oral cancer SCC T4N1M0 –/–
6 67 F Upper gingiva Oral cancer SCC T4N0M0 –/–
7 56 F Upper gingiva Oral cancer SCC T1N0M0 –/+
(left side)
[Upper gingiva Leukoplakia Dysplasia –
(right side) (mild)
8 74 M Upper gingiva Oral cancer SCC T4N0M0 –/–
9 66 F Tongue Oral cancer SCC T3N0M0 –/–
10 81 F Buccal mucosa Oral cancer SCC T2N1M0 –/–
11 51 M Tongue Oral cancer SCC T3N0M0 +/+
12 69 M Lower gingiva Oral cancer SCC T4N1M0 +/+
13 78 F Tongue Oral cancer SCC T2NxMx –/–
14 82 F Lower gingiva Oral cancer SCC T3N1M0 –/–
15 79 M Buccal mucosa Oral cancer SCC T1N0Mx –/–
[Buccal mucosa Leukoplakia Dysplasia –
(adjacent site) (moderate)
16 51 M Lower gingiva Leukoplakia Hyperplasia – +/+
17 53 M Lower gingiva Leukoplakia Hyperplasia – +/–
18 69 F Upper gingiva Erythroplakia Dysplasia – –/–
(moderate)
19 59 F Tongue Leukoplakia Dysplasia – –/–
(mild)
20 59 F Tongue Leukoplakia Dysplasia – –/–
(mild)
M, male; F, female; SCC, squamouns cell carcinoma.
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[lium were identified and precisely dissected from the tissue
sections under microscopic visualization. The scraped cells were
subsequently pelleted by centrifugation, and DNAs were extracted
by digesting the cells with a buffer containing 10 mM Tris–HCl (pH
7.5), 50 mM KCl, 1 mM EDTA, 1% SDS and 200 mg/ml proteinase
K at 37°C for 24–36 h, followed by 10 min of incubation at 100°C
to destroy any remaining proteinase K activity. The insoluble mate-
rials were pelleted by centrifugation, and aliquots of supernatant
were used directly in PCR reactions.
LOH analysis
Analysis of allelic losses was performed using a PCR-based
approach (Tsuchiya et al, 1992; Hung et al, 1995). Primers that
amplified polymorphic microsatellite markers were used for the
locus, D3S1300, which was at intron 5 of the FHIT gene. After
initial denaturation at 94°C for 4 min, 25 cycles of PCR were
performed, each consisting of 30 s at 94°C, 30 s at 65°C and 30 s
at 72°C. This was followed by 15 cycles consisting of 30 s at
90°C, 30 s at 65°C and 30 s at 72°C for denaturation, annealing
and extension, respectively, with the final extension at 72°C for 
2 min. PCR products were separated on a 6% urea-polyacrylamide
gel, and then radioactivity was evaluated by autoradiography with
a Fuji Bio-Image Analyser BAS 2000. For informative cases,
allelic loss was scored if the autoradiographic signal of one allele
was reduced in the tumor DNA, compared with the corresponding
normal allele.
RESULTS AND DISCUSSION
Abnormal FHIT transcripts in human oral SCCs
Total RNAs were prepared from 15 oral SCC tissue specimens.
RT-PCR analysis of SCC samples exhibited abnormalities of the
FHIT transcription in eight of 15 cases (53%) (Figure 1A).
However, none of nine normal oral epitheliums showed such
abnormalities (data not shown). Southern blot hybridization, using
an oligo-probe encoding within exon 10, verified that these prod-
ucts were derived from the FHIT gene (Figure 1B). Most of the
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Figure 1 Abnormalities of the FHIT transcripts in oral SCC. (A) Total RNAs
prepared from SCC tissues were analysed by nested RT-PCR as described
in Materials and Methods. A normal-size PCR product is indicated by an
arrow head. Patient numbers shown at the top of each lane are matched with
those in Table 1. Markers: commercial molecular weight marker (DNA ladder,
BRL). (B) Southern blot hybridization of RT-PCR products was performed
using a labelled oligo-probe encoding within exon 10 of the FHIT gene
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Figure 2 Sequence analysis of various patterns of the FHIT transcripts in oral SCC. White, shaded and closed boxes indicate untranslated exons, coding
exons and insertions, respectively. Solid lines linking these exons indicate the skipped regions. Arrow heads indicate the primers for RT-PCR. (A) Normal FHIT
transcript, (B) deletion of exons 5–8, (C) deletion of exons 5 and 6, insertion of 14 bp fragment, (D) deletion of exon 5, partial deletion of exon 6, (E) deletion of
exon 5, partial deletion of exon 6, insertion of 61 bp fragment, (F) deletion of exons 4–7, insertion of 84 bp fragment, (G) insertion of 124 bp or 179 bp fragmentFHIT abnormalities in oral carcinogenesis 841
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cases containing abnormal transcripts displayed both normal- and
abnormal-sized RT-PCR products, with abnormal-sized products
observed only in case Nos 7 and 9. Our results indicated that
abnormal FHIT transcripts occurred frequently in oral SCCs in
vivo, and thus agreed with the observations of previous in vitro
works using SCCs-derived cell lines (Mao et al, 1996; Virgilio et
al, 1996). Sequence analysis of RT-PCR products showed that the
deletion of exons 5 through 6, or through 8, of the FHIT cDNA,
which included the starting ATG codon of the FHIT protein, was
the most common abnormality. In these cases, various lengths 
(14 bp to 179 bp) of fragments which were unrelated to the
sequence of the FHIT gene were also observed (Figure 2). Extra
bands having a slightly larger size than that of the normal FHIT
transcript were found in two cases (Nos 10 and 12). Sequence
analysis confirmed that these bands represented FHIT transcripts
with a 124-bp or 179-bp insertion of unrelated fragments between
exons 4 and 5 respectively (data not shown). These insertions,
which seemed to be similar to those previously reported (Virgilio
et al, 1996; Fong et al, 1997), may affect translation fidelity, but
the role of such larger-sized transcripts is still unclear.
The simultaneous presence of wild-type and abnormal tran-
scripts observed here has also been seen in many other kinds of
tumour tissues and cell lines. It has been suggested that partial
deletions of the FHIT gene might affect transcription fidelity and
result in varying levels of abnormal transcripts. Mao suggested
another possibility, that abnormal transcripts might be derived
from subclones, since the FHIT gene contains a fragile site,
FRA3B (1998). Such mutations, though often seen in other tumour
suppressor genes, have not often been observed in the FHIT alleles
in tumour tissues and cell lines, and thus these findings may
contradict the notion that the FHIT gene is a classic tumour
suppressor gene in terms of its inactivation patterns and functions.
These results raise the possibility that the abnormal transcripts
may inhibit protein translations or trigger protein degradations, or
that they may encode truncated proteins which could act in a
dominant-negative manner.
LOH analysis of the FHIT gene with microdissected
DNA
Because the abnormal FHIT transcripts observed in various tissues
and cell lines, including non-neoplastic cells (Panagopoulos et al,
1997), might have included the products of alternative splicing, we
performed LOH analysis using the microsatellite marker D3S1300
located near exon 5 to confirm that these abnormalities could
actually be attributed to the FHIT gene. To eliminate possible
contamination of non-neoplastic cells, microdissection from
formalin-fixed sections of paraffin-embedded tumour samples was
performed for preparation of genomic DNAs from oral SCC cells
for LOH analysis. The results showed that allelic loss was present
in four of six SCC specimens that expressed abnormal FHIT tran-
scripts, with the other two cases being not informative (examples
in Figure 3 and Table 2). These findings suggest that the abnormal
FHIT transcripts found in this study can be attributed to abnormal-
ities of the FHIT gene, not to alternatively spliced transcripts.
A recent study found that LOH at the locus of the FHIT gene
was significantly more common in a group of smokers with lung
cancer than in a group of non-smokers with lung cancer (Sozzi et
al, 1997). Because epidemiological data have indicated a signifi-
cant association between cigarette smoking and development of
oral cancer (Takezaki et al, 1996), we compared the clinicopatho-
logical characteristics of oral SCC patients with the status of 
FHIT abnormalities (Table 1 and 2). However, FHIT status was
not correlated with any epidemiological factor, including age 
at cancer onset, sex, subsite, TNM classification, or tobacco or
alcohol consumption. The oral cavity is continuously exposed to
numerous compounds, including possible carcinogens, and the
pathway of oral tumorigenesis is considered to be more compli-
cated than that of the lung (Tanimoto et al, 1999), which may be
one reason that we were unable to discover any intimate relation-
ship between clinical characteristics and FHIT status in oral SCCs.
FHIT transcripts in human oral leukoplakia and
erythroplakia
FHIT transcripts from seven patients, six with leukoplakias and
one with erythroplakia, which included both histological epithelial
No. 2
N             T
No. 9
N            T
Figure 3 Representative examples of LOH at the 3p14.2 locus in oral SCC.
LOH analyses were performed using a microsatellite marker, D3S1300, as
described in Materials and Methods, and two LOH cases (Nos 2 and 9) are
depicted. N: paired normal tissue; T: tumour (SCC)
Table 2 Abnormalities of FHIT in oral SCC patients
Patient No FHIT transcript FHIT gene
Normal –
Deletion of exon 5; partial deletion of exon 6; 
insertion of 61 bp fragment LOH
Normal –
Deletion of exon 5 and 6; insertion of 14 bp fragment NI
Deletion of exon 5; partial deletion of exon 6 NI
Normal –
Deletion of exon 5 to 8 LOH
Normal –
Deletion of exon 5 to 8 LOH
Insertion of 124 bp fragment –
Normal –
Insertion of 179 bp fragment –
Normal –
Normal –
Deletion of exon 4 to 7; insertion of 84 bp fragment LOH
NI, not informative; –, not detected.
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hyperplasia and from slight to moderate dysplasia, were examined
to evaluate the involvement of FHIT abnormalities in the prema-
lignant lesions. Abnormal FHIT transcripts were found in two of
these samples (Nos 18 and 19; Figure 4). All patients were moni-
tored for at least 3 years after the excisions; with the exception of
patient No. 18 – in whom oral SCC arose at the upper gingival site
of the excision of the erythroplakia with abnormal FHIT tran-
scripts – no signs of malignant change were observed in any of the
patients. Comparing SCC and leukoplakia samples, both of which
were obtained simultaneously from the oral SCC patients,
abnormal FHIT transcripts were observed in tumors but not in
leukoplakias (Nos 7 and 15; Figure 4).
The occurrence of multiple oral cancers and the high incidence
of the second primary oral cancers can be explained by the field
cancerization theory, which proposes that prolonged exposure to
carcinogens leads to the independent transformation of multiple
epithelial cells over the entire exposed field (Slaughter et al, 1953;
Liciardello et al, 1989). This theory suggests that leukoplakias that
arise together with malignant lesions, as in two of our patients,
might have already accumulated genetic damages; to investigate
this possibility, we compared our simultaneusly obtained leuko-
plakia and SCC samples. In both cases, however, abnormal FHIT
transcripts were observed only in tumours, not in leukoplakia
samples (Nos 7 and 15; Figure 4). The FHIT gene, which is similar
to a yeast diadenosine hydrolase gene (Barnes et al, 1996), was
expected to be a candidate as a putative tumour suppressor gene,
but it has recently been suggested that the FHIT gene is not a selec-
tive target and that the 3p14 deletion results from the genomic
instability that may correlate in part with p53 gene inactivation
(Boldog et al, 1997). Recently, Siprashvili et al (1997) showed that
transfection of the FHIT gene into tumour cell lines which lacked
endogenous FHIT protein could significantly reduce tumour
formation and tumour size in nude mice but not in vitro.
Furthermore, their experiments using FHIT mutants indicated that
diadenosine hydrolase was not required for tumour suppression. 
In contrast, Otterson et al (1998) showed that expression of the
FHIT cDNA construct did not change the cell proliferation or 
alter tumorigenicity in animals. Interestingly, in both studies,
researchers observed no consistent effect of exogenous FHIT
expression on cell growth. In this study, it was elucidated that the
alteration of the FHIT gene is frequently seen in oral SCCs.
However, as mentioned above, the functional role of the FHIT
gene in the process of carcinogenesis is not yet well understood,
and, at present, the possibility of its being a tumour suppressor
gene is rather controversial.
Our study scale, particularly with respect to the premalignant
lesions, was too small to reach definite conclusions; however, our
findings suggest that FHIT abnormalities may not simply reflect
accumulation of genetic damage, and may work as a sensor of
genetic alterations rather than as a classical tumour suppressor
during oral carcinogenesis. If so, analysis of FHIT gene abnormal-
ities in small biopsy specimens may help to identify premalignant
lesions that already possess the potential to transform to malignan-
cies. To confirm this possibility, further investigation of the FHIT
alterations in various grades of epithelial dysplasia will be needed.
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